User:Aivu93/sandbox

Natalizumab, a new disease-modifying therapy for relapsing remitting multiple sclerosis (RRMS), is a humanized monoclonal antibody which binds to α4β1-integrin.^[1]

This is a user sandbox of Aivu93. You can use it for testing or practicing edits.
This is not the sandbox where you should draft your assigned article for a dashboard.wikiedu.org course.
To find the right sandbox for your assignment, visit your Dashboard course page and follow the Sandbox Draft link for your assigned article in the My Articles section.

Get Help

^ Hutchinson, Michael (2007-6). "Natalizumab: A new treatment for relapsing remitting multiple sclerosis". Therapeutics and Clinical Risk Management. 3 (2): 259–268. ISSN 1176-6336. PMC 1936307. PMID 18360634. {{cite journal}}: Check date values in: |date= (help)

[1] Hutchinson, Michael (2007-6). "Natalizumab: A new treatment for relapsing remitting multiple sclerosis". Therapeutics and Clinical Risk Management. 3 (2): 259–268. ISSN 1176-6336. PMC 1936307. PMID 18360634. {{cite journal}}: Check date values in: |date= (help)

[1]